SHERIDAN, Wyo., November 20, 2026. Xycota Biosciences, LLC (https://xycota.com), an independent, privately held central-nervous-system (CNS) biotechnology company developing standardized, non-hallucinogenic neuroplasticity candidates targeting the BDNF/TrkB pathway, today provided a scientific and operational update across its preclinical pipeline: lead outpatient candidate XYCO-02 for mild post-traumatic stress disorder (PTSD) and follow-on orphan neurology candidate XYCO-01 for frontotemporal dementia (FTD).
First-generation psychedelic clinical programs have established broad human safety pharmacology for psilocybin while highlighting two practical hurdles for scalable psychiatric and neurological care: 6-to-8-hour supervised in-clinic dosing sessions and functional unblinding exceeding 90 percent in published high-dose trials. Xycota Biosciences was founded to test a narrower, falsifiable translational question: whether a standardized, sub-perceptual psilocybin or psilocin regimen can engage neurotrophic synaptic signaling in humans without inducing an acute hallucinogenic experience or requiring full-day clinic stays.
Key Preclinical Pipeline & Operational Highlights
- XYCO-02 (Mild PTSD, Health Canada CTA in Preparation): Xycota is preparing a Canadian Clinical Trial Application (CTA) alongside contract research organization KGK Science Inc. (advised by Andrew Charrette, MSc, Director of Regulatory Affairs at KGK Science) for a proposed 28-day randomized, double-blind, placebo-controlled outpatient study of XYCO-02 in adults with mild PTSD. The proposed protocol is designed to evaluate changes on the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5), safety and tolerability, double-blind integrity across repeated outpatient dosing, and exploratory peripheral blood Brain-Derived Neurotrophic Factor (BDNF) levels.
- Peer-Reviewed Preclinical Mechanism (Neuropsychopharmacology, July 2026): Xycota's scientific rationale builds on a July 2026 peer-reviewed study in Neuropsychopharmacology (Ascone F, Buzzelli V, Mottarlini F, Trezza V, Hausman MS et al., 2026; 51(8):1454-1463; DOI: 10.1038/s41386-026-02361-x), led by external academic collaborator Associate Professor Viviana Trezza, PhD, at Roma Tre University and co-authored by Xycota Co-Founder and Chief Scientific Officer Marvin S. Hausman, MD. In male Fmr1 rats, repeated low-dose oral psilocybin (0.1 mg/kg p.o.) rescued object-recognition memory and normalized prefrontal cortex mature BDNF, TrkB, and pAKT/AKT ratios. Selective pharmacological blockade of 5-HT2A (M100907) or 5-HT1A (WAY-100635) receptors did not prevent the behavioral rescue in those rats, whereas selective blockade of the BDNF receptor TrkB (ANA-12) abolished it. Those findings were observed exclusively in a genetic rat model of Fragile X Syndrome, not in humans and not in a PTSD model.
- XYCO-01 (Frontotemporal Dementia) & Colorado Exosome Formulation Operations: Led operationally by Senior Lab Operations Manager Anthony Smith, PhD (PhD in Molecular and Cellular Biology, Oregon State University), Xycota's Colorado laboratory formulation program is developing characterized extracellular-vesicle (exosome) and liposomal reference formulations encapsulating active psilocin to investigate blood-brain-barrier transport for frontotemporal dementia (FTD). Xycota has filed an Orphan Drug Designation (ODD) request with the U.S. Food and Drug Administration (FDA) for XYCO-01 in FTD; that application remains under FDA review and has not been granted. Full preclinical animal biodistribution and FTD efficacy studies for XYCO-01 are sequenced behind clinical initiation of XYCO-02.
- Institutional Briefing & Sector Analyses: Qualified institutional life-science investors, pharmaceutical and biotechnology licensing executives, and clinical research institutions may view Xycota's 3-minute Investor Briefing film at https://xycota.com/investors, read our CNS Sector Landscape Comparison, or request NDA-gated diligence access at https://xycota.com/data-room.
“Working adults, veterans, first responders, and neurology families need rigorous drug development engineered around real-world outpatient life rather than full-day specialty clinic stays,” said Brad Listermann, Co-Founder and Chief Executive Officer of Xycota Biosciences. “As an independent, privately held biotech company, our focus is disciplined execution: completing our Health Canada CTA package with KGK Science for XYCO-02 and advancing our Colorado exosome formulation work for XYCO-01.”
“The 2026 rat receptor-blockade data gave us a clear mechanistic hypothesis to test,” said Marvin S. Hausman, MD, Co-Founder and Chief Scientific Officer of Xycota Biosciences, immunologist, former U.S. Public Health Service surgeon at the National Institutes of Health, and architect of six FDA-approved New Drug Applications. “Animal pharmacology never substitutes for human clinical data. Our proposed 28-day double-blind trial in mild PTSD is designed to test directly whether a sub-perceptual oral capsule produces a measurable clinical signal while preserving trial blinding.”
About Xycota Biosciences, LLC
Xycota Biosciences, LLC (https://xycota.com), headquartered in Sheridan, Wyoming, is an independent, privately held central-nervous-system (CNS) biotechnology company advancing preclinical candidates targeting BDNF/TrkB synaptic signaling. Lead investigational candidate XYCO-02 is a standardized sub-perceptual oral psilocybin capsule in Health Canada Clinical Trial Application preparation for mild PTSD. Follow-on investigational candidate XYCO-01 is an engineered exosome-encapsulated psilocin formulation for frontotemporal dementia (FDA Orphan Drug Designation request filed, not granted). Xycota is led by Co-Founders Brad Listermann (CEO) and Marvin S. Hausman, MD (CSO), Senior Lab Operations Manager Anthony Smith, PhD, and Board Director Lt. Col. Elton L. Johnson Jr., U.S. Army (Ret.). Xycota Biosciences, LLC has no public stock ticker, is not traded on any stock exchange or over-the-counter market, and is not party to any pending merger or acquisition transaction; any earlier third-party announcements referencing a proposed acquisition of Xycota are no longer in effect.
Investigational Status & Forward-Looking Statements Notice
All Xycota Biosciences candidates (XYCO-01 and XYCO-02) are preclinical and investigational, involve controlled substances handled exclusively through DEA- and Health Canada-licensed contract partners, and have not been approved by the U.S. Food and Drug Administration (FDA), Health Canada, or any regulatory authority. Neither candidate has been evaluated in a company-sponsored human clinical study, no clinical trial has been authorized or opened for recruitment, and no claims of human clinical safety or therapeutic efficacy are made. Filing an FDA Orphan Drug Designation request is an application step and does not guarantee designation or regulatory approval. Statements regarding proposed clinical trial applications, study designs, formulation programs, and development timelines are forward-looking and subject to scientific, regulatory, manufacturing, and financing risks that may cause actual outcomes to differ materially. Nothing in this release constitutes medical advice, investment advice, an offer to sell, or a solicitation of an offer to buy any security.
Media, Institutional Investor & Partnering Contact: Brad Listermann, Co-Founder & CEO | investors@xycota.com | brad@xycota.com | https://xycota.com/investors